文献速递区域麻醉与超声疼痛医学

周围神经阻滞中脂质体布比卡因并不优于普通布比卡因

Perineural Liposomal Bupivacaine Is Not Superior to Nonliposomal Bupivacaine for Peripheral Nerve Block Analgesia.
PubMed 文献 · Anesthesiology · 2021-01-01

该荟萃分析纳入9项随机试验共619例患者,比较周围神经阻滞使用脂质体布比卡因与非脂质体局麻药的镇痛效果。主要结局为24至72小时静息痛评分曲线下面积(AUC),脂质体布比卡因仅改善1.0 cm·h(95%CI 0.5至1.6;P=0.003),低于最小临床重要差异2.0 cm·h,且剔除一项企业赞助试验后差异无统计学意义。次要结局均无差异。

要点

  • 脂质体布比卡因对24至72小时疼痛AUC改善仅1.0 cm·h,低于临床重要阈值。
  • 剔除企业赞助试验后,组间差异无统计学意义(P=0.100)。
  • 术后镇痛药消耗、首次镇痛时间、副作用及功能恢复等次要结局均无差异。

核心结论

  • 周围神经阻滞使用脂质体布比卡因相比普通局麻药仅提供统计学显著但临床不重要的疼痛评分改善。
  • 高质量证据不支持周围神经阻滞中脂质体布比卡因优于非脂质体布比卡因。

研究设计与样本

  • 荟萃分析纳入9项随机试验,共619例患者,比较脂质体布比卡因与非脂质体局麻药用于周围神经阻滞的镇痛效果。
  • 主要结局为24至72小时静息痛评分曲线下面积(AUC),最小临床重要差异设为2.0 cm·h。

主要发现

  • 非脂质体与脂质体布比卡因组24至72小时AUC疼痛评分分别为7.6±4.9 cm·h和6.6±4.6 cm·h。
  • 脂质体布比卡因改善AUC的差值为1.0 cm·h(95%CI 0.5至1.6;P=0.003)。
  • 剔除一项企业赞助试验后,差值变为0.7 cm·h(95%CI -0.1至1.5;P=0.100),无统计学意义。
  • 次要结局包括镇痛药消耗、首次镇痛时间、阿片相关副作用、患者满意度、住院时长和功能恢复均无差异。
  • 未报告脂质体布比卡因相关副作用。

关键数值与推荐

  • AUC疼痛评分最小临床重要差异为2.0 cm·h。
  • 脂质体布比卡因组AUC改善1.0 cm·h(95%CI 0.5至1.6;P=0.003),未达临床重要阈值。
  • 剔除企业赞助试验后差值0.7 cm·h(95%CI -0.1至1.5;P=0.100)。

临床怎么用

  • 周围神经阻滞时不应常规优先选用脂质体布比卡因,因临床获益不显著。
  • 决策时应考虑证据受企业赞助试验影响,剔除后获益消失。

局限性

  • 纳入试验中存在一项企业赞助试验,可能影响汇总结果。
  • 未报告脂质体布比卡因副作用,但证据来自有限试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liposomal bupivacaine is purported to extend analgesia of peripheral nerve blocks when administered perineurally. However, evidence of the clinical effectiveness of perineural liposomal bupivacaine is mixed. This meta-analysis seeks to evaluate the effectiveness of perineural liposomal bupivacaine in improving peripheral nerve block analgesia as compared with nonliposomal local anesthetics. METHODS: The authors identified randomized trials evaluating the effectiveness of peripheral nerve block analgesic that compared liposomal bupivacaine with nonliposomal local anesthetics. The primary outcome was the difference in area under the receiver operating characteristics curve (AUC) of the pooled 24- to 72-h rest pain severity scores. Secondary outcomes included postoperative analgesic consumption, time to first analgesic request, incidence of opioid-related side effects, patient satisfaction, length of hospital stay, liposomal bupivacaine side effects, and functional recovery. AUC pain scores were interpreted in light of a minimal clinically important difference of 2.0 cm · h. RESULTS: Nine trials (619 patients) were analyzed. When all trials were pooled, AUC pain scores ± SD at 24 to 72 h were 7.6 ± 4.9 cm · h and 6.6 ± 4.6 cm · h for nonliposomal and liposomal bupivacaine, respectively. As such, perineural liposomal bupivacaine provided a clinically unimportant benefit by improving the AUC (95% CI) of 24- to 72-h pain scores by 1.0 cm · h (0.5 to 1.6; P = 0.003) compared with nonliposomal bupivacaine. Excluding an industry-sponsored trial rendered the difference between the groups nonsignificant (0.7 cm · h [-0.1 to 1.5]; P = 0.100). Secondary outcome analysis did not uncover any additional benefits to liposomal bupivacaine in pain severity at individual timepoints up to 72 h, analgesic consumption, time to first analgesic request, opioid-related side effects, patient satisfaction, length of hospital stay, and functional recovery. No liposomal bupivacaine side effects were reported. CONCLUSIONS: Perineural liposomal bupivacaine provided a statistically significant but clinically unimportant improvement in the AUC of postoperative pain scores compared with plain local anesthetic. Furthermore, this benefit was rendered nonsignificant after excluding an industry-sponsored trial, and liposomal bupivacaine was found to be not different from plain local anesthetics for postoperative pain and all other analgesic and functional outcomes. High-quality evidence does not support the use of perineural liposomal bupivacaine over nonliposomal bupivacaine for peripheral nerve blocks.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Hussain N, Brull R, Sheehy B, et al. Perineural Liposomal Bupivacaine Is Not Superior to Nonliposomal Bupivacaine for Peripheral Nerve Block Analgesia. Anesthesiology. 2021. PMID: 33372953. doi:10.1097/ALN.0000000000003651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。